Sugar Maple Asset Management LLC Makes New $122,000 Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Sugar Maple Asset Management LLC purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 26,250 shares of the company’s stock, valued at approximately $122,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of GoodRx in the third quarter worth approximately $33,000. Fortem Financial Group LLC raised its stake in shares of GoodRx by 7.2% in the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock worth $554,000 after purchasing an additional 7,996 shares during the last quarter. XTX Topco Ltd raised its stake in shares of GoodRx by 42.4% in the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after purchasing an additional 8,801 shares during the last quarter. Canada Pension Plan Investment Board raised its stake in shares of GoodRx by 5.9% in the second quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock worth $1,296,000 after purchasing an additional 9,200 shares during the last quarter. Finally, EP Wealth Advisors LLC purchased a new stake in shares of GoodRx in the third quarter worth approximately $73,000. Institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GDRX. Morgan Stanley dropped their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. KeyCorp dropped their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Mizuho began coverage on GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Finally, Citigroup dropped their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, GoodRx currently has an average rating of “Moderate Buy” and a consensus target price of $8.38.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $4.57 on Tuesday. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average of $4.59 and a 200-day moving average of $6.43.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.